Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Coronary thrombolysis: round two and beyond.

× No keyword cloud information.

9 in total

1. Effects of alteplase in acute myocardial infarction: 6-month results from the ASSET study. Anglo-Scandinavian Study of Early Thrombolysis.

Authors: R G Wilcox; G von der Lippe; C G Olsson; G Jensen; A M Skene; J R Hampton
Journal: Lancet Date: 1990-05-19 Impact factor: 79.321

2. Antistreptokinase titres after intravenous streptokinase.

Authors: S Jalihal; G K Morris
Journal: Lancet Date: 1990-01-27 Impact factor: 79.321

3. Promotion of thrombin activity by thrombolytic therapy without simultaneous anticoagulation.

Authors: H J Rapold
Journal: Lancet Date: 1990-02-24 Impact factor: 79.321

4. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis.

Authors: R D Hull; G E Raskob; J Hirsh; R M Jay; J R Leclerc; W H Geerts; D Rosenbloom; D L Sackett; C Anderson; L Harrison
Journal: N Engl J Med Date: 1986-10-30 Impact factor: 91.245

5. An objective study of alternative methods of heparin administration.

Authors: P G Bentley; V V Kakkar; M F Scully; I R MacGregor; P Webb; P Chan; N Jones
Journal: Thromb Res Date: 1980 Apr 1-15 Impact factor: 3.944

6. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator.

Authors: K L Neuhaus; W Feuerer; S Jeep-Tebbe; W Niederer; A Vogt; U Tebbe
Journal: J Am Coll Cardiol Date: 1989-11-15 Impact factor: 24.094

7. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators.

Authors: J Hsia; W P Hamilton; N Kleiman; R Roberts; B R Chaitman; A M Ross
Journal: N Engl J Med Date: 1990-11-22 Impact factor: 91.245

8. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction.

Authors: E J Topol; B S George; D J Kereiakes; D C Stump; R J Candela; C W Abbottsmith; L Aronson; A Pickel; J M Boswick; K L Lee
Journal: Circulation Date: 1989-02 Impact factor: 29.690

9. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator.

Authors: M Verstraete; R Bernard; M Bory; R W Brower; D Collen; D P de Bono; R Erbel; W Huhmann; R J Lennane; J Lubsen
Journal: Lancet Date: 1985-04-13 Impact factor: 79.321

9 in total

2 in total

Review 1. New thrombolytic strategy: bolus administration of tPA and urokinase-fibrinogen conjugate.

Authors: A V Maksimenko; E G Tischenko
Journal: J Thromb Thrombolysis Date: 1999-06 Impact factor: 2.300

2. Intracerebral haemorrhage after thrombolytic therapy for acute myocardial infarction.

Authors: R S More; R Vincent
Journal: Postgrad Med J Date: 1992-10 Impact factor: 2.401

2 in total